1 Undervalued Growth Stock Down 8% to Buy Before 2026

Eli Lilly (LLY) is positioned for significant growth despite a recent stock dip and high forward P/E, driven by its leading presence in the burgeoning weight management market. The company's drug tirzepatide (Zepbound) is now projected to achieve $62 billion in annual sales by 2030, while the upcoming oral GLP-1 medicine, orforglipron, is expected to contribute up to $12.7 billion. These pipeline strengths are anticipated to propel Lilly to potentially become the world's top-selling pharmaceutical company, justifying its valuation and offering strong dividend growth for investors.

Analysis

Eli Lilly (LLY) has experienced an 8% stock decline over the trailing-12-month period due to a clinical setback and broader market factors, though this is viewed as a temporary dip. Despite trading at a premium 27 times forward earnings, significantly above the healthcare industry average of 17.5, this valuation is supported by the company's "abnormal" top-line growth over the past two years, surpassing rivals like Novo Nordisk.
The company's robust growth outlook is primarily fueled by its leadership in the expanding weight management market. Its flagship drug, tirzepatide (Zepbound), is now projected to achieve up to $62 billion in annual sales by 2030, a substantial increase from earlier $25 billion peak estimates and its $14.7 billion in first-half sales. This positions tirzepatide as an exceptionally high-performing therapy.

Further strengthening its pipeline, Eli Lilly is advancing orforglipron, an oral GLP-1 medicine that demonstrated strong results in late-stage trials and could generate up to $12.7 billion in sales by 2030. This oral option addresses patient preference and cost, complementing tirzepatide. These combined growth drivers are anticipated to elevate Lilly to potentially become the world's top-selling pharmaceutical company, validating its strong growth potential and current valuation.

Key Decisions for Investors

• Investors should consider Eli Lilly for long-term growth portfolios, given its leading position in the high-growth weight management market and robust pipeline projections for tirzepatide and orforglipron.
• Closely monitor the continued sales performance of tirzepatide and the successful commercial launch and adoption of orforglipron, as these are critical for realizing the company's ambitious growth targets and maintaining market leadership.
• Evaluate the stock for its dividend growth potential, as consistent payout increases with a reasonable payout ratio offer a compelling aspect for income-focused investors alongside capital appreciation.